Staedtisches Klinikum Braunschweig gGmbH

At Staedtisches Klinikum Braunschweig gGmbH, clinical research in urology is centered on neoplasms, especially cancers affecting the prostate and other solid tumors. The studies focus on testing new treatment approaches, checking safety, and improving how well therapies control disease.

• Research on prostate cancer, including high-risk, locally advanced, and recurrent disease
• Studies in Ewing sarcoma aimed at improving event-free survival and treatment outcomes
• Trials in mature aggressive B-cell lymphoma and leukemia in children and adolescents assessing better disease control

Overall, the site supports a focused oncology portfolio that includes evaluating new hormonal therapies, refining local cancer treatment, and improving survival for patients with difficult-to-treat malignancies.

Several trials at this hospital examine advanced treatment strategies for prostate cancer, with attention to high-risk localized, locally advanced, and recurrent disease. The goal is to improve disease control and long-term outcomes while also assessing safety and effectiveness.

• Testing androgen receptor-targeted therapy for men receiving radiation therapy
• Evaluating treatment options before and after surgery in high-risk disease
• Studying a new local approach for recurrent prostate cancer

These studies explore whether newer hormonal and local therapies can better prevent progression and improve response compared with current standard care.

The site also contributes to research in pediatric oncology, with trials for Ewing sarcoma and mature aggressive B-cell lymphoma or leukemia in younger patients. These studies aim to improve survival while reducing treatment-related burden.

• Optimizing therapy for Ewing sarcoma to improve event-free survival
• Assessing whether treatment changes can maintain outcomes in children with limited B-cell non-Hodgkin lymphoma
• Studying immune recovery and effectiveness of added rituximab in advanced pediatric blood cancers

This research focuses on making cancer treatment more effective for children and adolescents, while also examining whether therapy can be simplified without losing benefit.